Pharmexa-Epimmune begins phase 1 study of HIV vaccines

By Angela McDaniels

Seattle, Jan. 27 - Pharmexa-Epimmune Inc. said it has begun a phase 1 study with the HIV Vaccine Trials Network to test the safety of two HIV vaccine candidates developed by the company.

The trial will also test whether the two study vaccines, which are designed for use in combination, cause appropriate immune response.

The first study vaccine, EP HIV-1090, is a DNA plasmid that has been tested previously in humans and shown to be safe, according to a company news release. The second study vaccine, EP-1043, is a recombinant protein that is being tested in humans for the first time.

The escalating-dose, placebo-controlled, double-blind trial will enroll about 120 people in the United States and Peru and is sponsored by the National Institutes of Health's Division of AIDS.

Pharmexa-Epimmune is a U.S. subsidiary of Pharmexa AS, a Horsholm, Denmark-based company that develops immunotherapy and vaccines for the treatment of chronic and infectious diseases.

The HIV Vaccine Trials Network is a Seattle-based, international collaboration of scientists and institutions devoted to developing an HIV vaccine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.